---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-013402"
form_type: "8-K"
ticker: "ADMA"
cik: "0001368514"
company_name: "ADMA BIOLOGICS, INC."
filed_at: "2023-03-23T23:59:59+00:00"
generated_at: "2026-06-17T17:50:49.514357+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# ADMA Q4 revenue $50M (+90% YoY); FY 2023 guidance >$210M, first-time EBITDA in H2 2023

## Summary
- Q4 2022 total revenues $50.0M (+90% YoY); gross profit $14.2M (vs $3.5M); net loss $12.2M ($0.06 loss per share).
- Full year 2022 revenues $154.1M (+90% YoY); net loss $65.9M (improved from $71.6M).
- FY 2023 total revenue expected to exceed $210M; first-time positive EBITDA no later than second half 2023.
- 2024-2025 revenue targets: $250M+ in 2024, $300M+ thereafter; gross margins 40-50%, net income margins 20-30%.
- ASCENIV production to expand to 4,400L scale; BioCenters on track for 10 FDA-licensed sites by year-end 2023; strategic review continues with Morgan Stanley.

## SEC filing metadata
- accession: 0001140361-23-013402
- form_type: 8-K
- ticker: ADMA
- cik: 0001368514
- company_name: ADMA BIOLOGICS, INC.
- filed_at: 2023-03-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1368514/000114036123013402/0001140361-23-013402-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1368514/000114036123013402/brhc10050204_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-013402
- JSON: https://secwatch.observer/filing/0001140361-23-013402.json
- Plain text: https://secwatch.observer/filing/0001140361-23-013402.txt

## Key facts
- Earnings Releases
  ADMA BIOLOGICS, INC. reported the three months ended December 31, 2022 results: revenue $50.0 million.
  - Period: the three months ended December 31, 2022
  - Revenue: $50.0 million
  - Result: reported results
  source text: Total revenues for the quarter ended December 31, 2022 were $50.0 million, as compared to $26.4 million during the fourth quarter of 2021, an increase of $23.6 million, or approximately 90%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1368514/000114036123013402/0001140361-23-013402-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.